Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

7 Cryptos to Carefully Scrutinize After Jamie Dimon’s Controversial Claims

By Josh Enomoto, InvestorPlace Contributor

Are cryptos truly worthless as JPMorgan Chase CEO Jamie Dimon claimed? Probably not, but some of them are certainly better than others.

ReWalk Robotics is a Catch-22 Investment

By Josh Enomoto, InvestorPlace Contributor

While the surface-level narrative for RWLK stock is exceptionally compelling, the science and the economics are questionable.

Zomedica Stock Will Need More Than a Change in Management to Bounce Back

By Josh Enomoto, InvestorPlace Contributor

While a C-suite scenery change might be good for Zomedica, the shift may not provide a similar outcome for ZOM stock.

Aterian’s Acknowledged Risk Factors Should Make You Think Twice

By Josh Enomoto, InvestorPlace Contributor

The surface-level narrative for ATER stock might appeal to speculators but it’s upside potential is outside company control.

Vinco Ventures Shows Why You Can’t Trust a 6-Foot Man

By Josh Enomoto, InvestorPlace Contributor

While there’s plenty of buzzwords surrounding BBIG stock, the underlying narrative around Venco Ventures falls short against any standards.

Clover Health Stock Is Still Risky, But Speculators Could Consider It

By Josh Enomoto, InvestorPlace Contributor

While conservative investors will want to stay away from risky CLOV stock, speculators can play its recent news item.

4 Stocks to Sell (and 4 to Buy) Amid Facebook’s Whistleblower Scandal

By Josh Enomoto, InvestorPlace Contributor

With the Facebook scandal possibly forcing a greater response by social media, here are the stocks to sell (and buy) from the PR crisis.

Joby Aviation’s Innovation Doesn’t Merit Taking a ‘Flyer’ on JOBY Stock

By Josh Enomoto, InvestorPlace Contributor

While JOBY stock may offer an investment into the future of personal air mobility, you shouldn’t ignore its major risks.

7 Best Blue-Chip Stocks to Buy as China Shakes the Market

By Josh Enomoto, InvestorPlace Contributor

Although the China Evergrande crisis sent a wave of worries to the market, these blue-chip stocks may offer a viable discount to investors.

Hippo Holdings Suffrers From Much More Than Generalized SPAC Exhaustion

By Josh Enomoto, InvestorPlace Contributor

While HIPO stock is connected to the relevant tech-based insurance services sector, economic challenges pose serious concerns.

Load More